Challenging Cases in BRAF-Mutated Melanoma: Applying the Latest Advances to Optimize Care

Target Audience
The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with cutaneous melanoma.

Program Overview
Advances in BRAF-targeted agents and their integration into treatment algorithms for patients with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. Although the rapid expansion in available treatment options has improved patient outcomes, physicians are now challenged to select from multiple classes of therapies and combinations, particularly with the increased use of triple therapy regimens combining PD-1 blockade with BRAF/MEK inhibitors. Additionally, the optimal sequencing of regimens for treating advanced BRAF-mutated melanoma remains an active area of investigation. In this case-based educational activity, experts will review clinical examples that highlight patients with BRAF-positive melanoma who may benefit from neoadjuvant and/or adjuvant treatment. Faculty will also discuss the latest evidence regarding the use of triple therapy for patients with BRAF-mutated melanoma as well as updates on the management of patients with brain metastases.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Evaluate patients with BRAF-positive melanoma who may benefit from neoadjuvant and/or adjuvant treatment.
Assess the latest evidence regarding the use of triple therapy combinations for patients with BRAF-positive melanoma and how these strategies may fit into existing treatment paradigms.
Examine the latest evidence regarding the burden of brain metastases in patients with advanced melanoma.